Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)
CAPS Rating:
A development-stage biopharmaceutical company dedicated to the discovery, development and eventual commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.
RSS Headlines
Fool UK